More NewsRead More
Can-Fite Completes the Design of the Rheumatoid Arthritis Phase III Study of Its Lead Drug Candidate CF101
December 30, 2014
Second Part of the Glaucoma Phase II study has been Approved in a European Country
December 15, 2014
Can-Fite Announces $8 Million At-The-Market Registered Direct Offering
December 02, 2014
US Researchers Published Scientific Findings that are a Potential Breakthrough for Prevention of Neuropathic Pain by CF101
December 01, 2014
Can-Fite Near-Term Milestones Timetable for 2014/2015
November 18, 2014
Can-Fite Announces Special General Meeting of Shareholders to Elect External Director
November 17, 2014
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here